Standout Papers

Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by... 2000 2026 2008 2017 3.7k
  1. Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors (2000)
    Elisabeth Buchdunger, Catherine L. Cioffi et al. Journal of Pharmacology and Experimental Therapeutics
  2. Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor (2001)
    Heikki Joensuu, Peter Roberts‎ et al. New England Journal of Medicine
  3. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor (2000)
    Michael C. Heinrich, Diana Griffith et al. Blood
  4. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (2001)
    Brian Druker, Moshe Talpaz et al. New England Journal of Medicine
  5. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants (2005)
    Thomas O’Hare, Denise K. Walters et al. Cancer Research
  6. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2009)
    Andreas Hochhaus, S G O'Brien et al. Leukemia
  7. Translation of the Philadelphia chromosome into therapy for CML (2008)
    Brian Druker Blood
  8. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML (2013)
    Julia E. Maxson, Jason Gotlib et al. New England Journal of Medicine
  9. The development of imatinib as a therapeutic agent for chronic myeloid leukemia (2004)
    Michael W. Deininger, Elisabeth Buchdunger et al. Blood
  10. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study (2008)
    Richard A. Larson, Brian Druker et al. Blood
  11. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. (1996)
    Elisabeth Buchdunger, J. Zimmermann et al. PubMed
  12. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability (2010)
    Brian J. Lannutti, Sarah Meadows et al. Blood
  13. Response and Resistance to BCR-ABL1-Targeted Therapies (2020)
    Theodore P. Braun, Christopher A. Eide et al. Cancer Cell
  14. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (2003)
    Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology
  15. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia (2002)
    Hagop Kantarjian, Charles L. Sawyers et al. New England Journal of Medicine
  16. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia (2000)
    Brian Druker, Nicholas Lydon Journal of Clinical Investigation
  17. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012)
    Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine
  18. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (2002)
    Andreas Hochhaus, Sebastian Kreil et al. Leukemia
  19. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (2010)
    Amie S. Corbin, Anupriya Agarwal et al. Journal of Clinical Investigation
  20. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells (1996)
    Brian Druker, Shu Tamura et al. Nature Medicine
  21. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017)
    Andreas Hochhaus, Richard A. Larson et al. New England Journal of Medicine
  22. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome (2001)
    Brian Druker, Charles L. Sawyers et al. New England Journal of Medicine

Immediate Impact

15 by Nobel laureates 54 from Science/Nature 117 standout
Sub-graph 1 of 16

Citing Papers

Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor
2019 StandoutScience
Personalized medicine: Time for one-person trials
2015 StandoutNature

Works of Brian Druker being referenced

A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia
2014
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout

Author Peers

Author Last Decade Papers Cites
Brian Druker 29898 21325 13369 17055 597 54.0k
Moshe Talpaz 28654 22419 12929 10816 765 44.0k
Charles L. Sawyers 15494 11397 6821 24460 263 52.5k
Francis J. Giles 20046 15414 6250 14728 778 41.0k
Andreas Hochhaus 29429 23691 15371 5953 819 39.2k
Michael J. Keating 20959 30311 1947 21086 1.1k 65.3k
James D. Griffin 12277 6230 2655 12646 352 29.3k
William G. Wierda 10760 17768 1344 8334 821 30.9k
Guillermo Garcia‐Manero 29771 14343 4360 17388 1.5k 42.9k
John M. Goldman 21809 13997 8428 5044 486 29.2k
Razelle Kurzrock 6804 6704 2836 20512 1.2k 58.6k

All Works

Loading papers...

Rankless by CCL
2026